Skeletal Research Group, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
Institute of Biomedical and Environmental Health Research, University of the West of Scotland, Paisley, UK.
Br J Pharmacol. 2019 Jan;176(1):38-51. doi: 10.1111/bph.14173. Epub 2018 Mar 30.
Cartilage destruction is a key characteristic of arthritic disease, a process now widely established to be mediated by metzincins such as MMPs. Despite showing promise in preclinical trials during the 1990s, MMP inhibitors for the blockade of extracellular matrix turnover in the treatment of cancer and arthritis failed clinically, primarily due to poor selectivity for target MMPs. In recent years, roles for serine proteinases in the proteolytic cascades leading to cartilage destruction have become increasingly apparent, renewing interest in the potential for new therapeutic strategies that utilize pharmacological inhibitors against this class of proteinases. Herein, we describe key serine proteinases with likely importance in arthritic disease and highlight recent advances in this field. LINKED ARTICLES: This article is part of a themed section on Translating the Matrix. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.1/issuetoc.
软骨破坏是关节炎疾病的一个关键特征,这一过程现在被广泛认为是由基质金属蛋白酶(MMPs)等金属蛋白酶介导的。尽管在 20 世纪 90 年代的临床前试验中显示出前景,但用于阻断癌症和关节炎中细胞外基质转化的 MMP 抑制剂在临床上失败了,主要是由于对靶 MMP 的选择性差。近年来,丝氨酸蛋白酶在导致软骨破坏的蛋白水解级联中的作用变得越来越明显,这重新激发了人们对利用针对这类蛋白酶的药理学抑制剂的新治疗策略的兴趣。本文描述了在关节炎疾病中可能具有重要意义的关键丝氨酸蛋白酶,并强调了该领域的最新进展。相关文章:本文是翻译基质专刊的一部分。要查看本部分的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.1/issuetoc.